Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo.
暂无分享,去创建一个
S. Kanner | A. Raitano | Z. An | J. Gudas | X. Jia | A. Jakobovits | J. Pérez-Villar | K. Morrison | K. Morrison | P. Challita-Eid | K. Morrison | S. Etessami | J. Perez-Villar | J. J. Perez-Villar
[1] A. Levine,et al. The regulation of exosome secretion: a novel function of the p53 protein. , 2006, Cancer research.
[2] J. Soria,et al. STEAP, a prostate tumor antigen, is a target of human CD8+ T cells , 2006, Cancer Immunology, Immunotherapy.
[3] N. Bander,et al. Antibody-based therapeutics: Focus on prostate cancer , 2005, Cancer and Metastasis Reviews.
[4] J. J. Sharp,et al. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells , 2005, Nature Genetics.
[5] Zhennan Gu,et al. Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. , 2005, Cancer research.
[6] F. Lemonnier,et al. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. , 2005, Cancer research.
[7] Sherine F. Elsawa,et al. Recognition of Six-Transmembrane Epithelial Antigen of the Prostate–Expressing Tumor Cells by Peptide Antigen–Induced Cytotoxic T Lymphocytes , 2005, Clinical Cancer Research.
[8] B. Müller-Tiemann,et al. Targeting tomoregulin for radioimmunotherapy of prostate cancer. , 2005, Cancer research.
[9] A. Valencia,et al. ACRATA: a novel electron transfer domain associated to apoptosis and cancer , 2004, BMC Cancer.
[10] Eric Ibsen,et al. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. , 2004, Molecular cancer therapeutics.
[11] A. Chakrabarty,et al. Regulation of Mammalian Cell Growth and Death by Bacterial Redox Proteins: Relevance to Ecology and Cancer Therapy , 2004, Cell cycle.
[12] Wei Zhang,et al. Increased invasive capacity of connexin43-overexpressing malignant glioma cells. , 2003, Journal of neurosurgery.
[13] Wei Zhang,et al. Communication between malignant glioma cells and vascular endothelial cells through gap junctions. , 2003, Journal of neurosurgery.
[14] T. Steinberg,et al. Activation of L-type Calcium Channels Is Required for Gap Junction-mediated Intercellular Calcium Signaling in Osteoblastic Cells* , 2003, The Journal of Biological Chemistry.
[15] P. Mehta,et al. Impaired Trafficking of Connexins in Androgen-independent Human Prostate Cancer Cell Lines and Its Mitigation by α-Catenin* , 2002, The Journal of Biological Chemistry.
[16] M. Rubin,et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. , 2002, Cancer research.
[17] C. Naus. Gap junctions and tumour progression. , 2002, Canadian journal of physiology and pharmacology.
[18] R. Hubert,et al. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[19] C. McCulloch,et al. Biochemical and functional characterization of intercellular adhesion and gap junctions in fibroblasts. , 2000, American journal of physiology. Cell physiology.
[20] R. Hubert,et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[21] E. Fearon,et al. Cancer progression , 1999, Current Biology.
[22] M. Loda,et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[23] K. A. Klein,et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice , 1997, Nature Medicine.
[24] C. Naus,et al. A pre-loading method of evaluating gap junctional communication by fluorescent dye transfer. , 1995, BioTechniques.
[25] O. Witte,et al. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias , 1991, Molecular and cellular biology.
[26] Xi Lin,et al. Changes in gap junctional connexin isoforms during prostate cancer progression , 2006, The Prostate.
[27] P. Carter,et al. Tunable antibodies , 2005, Nature Biotechnology.